Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer

[1]  R. Jove,et al.  Targeting JAK1/STAT3 Signaling Suppresses Tumor Progression and Metastasis in a Peritoneal Model of Human Ovarian Cancer , 2014, Molecular Cancer Therapeutics.

[2]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[3]  P. Jänne,et al.  The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.

[4]  J. Engelman,et al.  Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer , 2013, Science Signaling.

[5]  X. Pivot,et al.  Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. , 2013, Clinical colorectal cancer.

[6]  Lin Wang,et al.  Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer , 2012, Clinical Cancer Research.

[7]  Gur Pines,et al.  The ERBB network: at last, cancer therapy meets systems biology , 2012, Nature Reviews Cancer.

[8]  I. Cree,et al.  Targeting EGFR and PI3K pathways in ovarian cancer , 2012, British Journal of Cancer.

[9]  Gordon B Mills,et al.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.

[10]  R. Figlin,et al.  Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. , 2011, Cancer research.

[11]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[12]  B. Stordal,et al.  Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[13]  C. Rancourt,et al.  Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients , 2011, BMC Cancer.

[14]  R. Perez-soler,et al.  Treatment of non-small-cell lung cancer with erlotinib or gefitinib. , 2011, The New England journal of medicine.

[15]  R. Jove,et al.  The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival , 2011, Leukemia.

[16]  Q. Sheng,et al.  The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer , 2011, British Journal of Cancer.

[17]  Helen X. Chen,et al.  Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. , 2010, Gynecologic oncology.

[18]  E. Haura,et al.  A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  A. Gemma,et al.  F1000 highlights , 2010 .

[20]  P. Yue,et al.  Enhanced Sensitivity of Pancreatic Cancer Cells to Concurrent Inhibition of Aberrant Signal Transducer and Activator of Transcription 3 and Epidermal Growth Factor Receptor or Src , 2010, Journal of Pharmacology and Experimental Therapeutics.

[21]  R. Jove,et al.  Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling. , 2010, Carcinogenesis.

[22]  M. Cristea,et al.  Review: Practical considerations in ovarian cancer chemotherapy , 2010, Therapeutic advances in medical oncology.

[23]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[24]  S. Campos,et al.  A Current Review of Targeted Therapeutics for Ovarian Cancer , 2010, Journal of oncology.

[25]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[26]  G. Mills,et al.  Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges , 2009, Journal of oncology.

[27]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[28]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[29]  Timothy A. Yap,et al.  Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.

[30]  Timothy C Wang,et al.  Inflammation and cancer: IL-6 and STAT3 complete the link. , 2009, Cancer cell.

[31]  F. Ali-Osman,et al.  Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High-Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and Alkylators , 2008, Clinical Cancer Research.

[32]  D. Yee,et al.  Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. , 2008, The Journal of clinical investigation.

[33]  I. Brandslund,et al.  Mutant Epidermal Growth Factor Receptor in Benign, Borderline, and Malignant Ovarian Tumors , 2008, Clinical Cancer Research.

[34]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[35]  R. Bast,et al.  The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis , 2006, Cancer.

[36]  J. Baselga,et al.  The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy , 2006, Clinical Cancer Research.

[37]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[38]  J. Soria,et al.  Response of ovarian carcinomas to gefitinib–carboplatin–paclitaxel combination is not associated with EGFR kinase domain somatic mutations , 2006, International journal of cancer.

[39]  David L Rimm,et al.  Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer , 2005, Clinical Cancer Research.

[40]  A. Godwin,et al.  Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study , 2005, Clinical Cancer Research.

[41]  R. Edwards,et al.  Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study , 2004, International Journal of Gynecologic Cancer.

[42]  A. Dowlati,et al.  Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. , 2004, Molecular cancer therapeutics.

[43]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[44]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[46]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[47]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[48]  C. Kainz,et al.  Serum evaluation of interleukin 6 in ovarian cancer patients. , 1997, Gynecologic oncology.

[49]  H. Sasano,et al.  Expression of Epidermal Growth Factor‐Related Proteins and Epidermal Growth Factor Receptor in Common Epithelial Ovarian Tumors , 1997, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[50]  S. Kain,et al.  An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells. , 1996, Analytical biochemistry.

[51]  P. Sismondi,et al.  The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. , 1996, British Journal of Cancer.

[52]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[53]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[54]  H. Heinzl,et al.  EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. , 1997, Anticancer research.

[55]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.